Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9555919 | 0.87 | HTR7 (0.61) | HTR7HTR2AHTR1ADRD2DRD3 | |
| SCHEMBL6402560 | 0.84 | HRH1 (0.55) | HRH1 | |
| SCHEMBL7055287 | 0.80 | HTR1A (0.50) | HTR7HTR2AHTR1ADRD2DRD3 | |
| SCHEMBL5109440 | 0.80 | CCR3 (0.45) | HTR2AHTR1ADRD2DRD3HRH1 | |
| SCHEMBL7057916 | 0.78 | HRH1 (0.59) | HTR7HTR1ADRD2DRD3HRH1 | |
| SCHEMBL2250329 | 0.77 | MAOB (0.59) | HTR7HTR1ADRD2DRD3HRH1 | |
| SCHEMBL5099023 | 0.77 | HRH3 (0.44) | HTR7HTR2ADRD2HRH1MAOB | |
| SCHEMBL26992312 | 0.76 | HTR1A (0.62) | HTR7HTR1ADRD2DRD3HRH1 | |
| SCHEMBL29459507 | 0.76 | HTR1A (0.62) | HTR7HTR1ADRD2DRD3HRH1 | |
| SCHEMBL7057848 | 0.76 | DRD2 (0.59) | HTR7HTR1ADRD2DRD3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348341-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2008-03-25 | — | — | US | disclosed |
| US-20030166652-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166652-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HTR7 2295/4885HTR2A 3289/4885HTR1A 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.